Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) therapy of malignant gliomas

Journal of Neuro-Oncology

Volumn 65, Issue 1, 2003, Pages 3-14

  Weaver, Michael ^a   Laske, Douglas W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Convection enhanced delivery; Diphtheria toxin; Glioblastoma multiforme (GBM); Malignant brain tumor; Targeted toxin; Transferrin; Transferrin receptor

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CEFTRIAXONE; CHLOROQUINE; CRM107; DAB 389 EPIDERMAL GROWTH FACTOR; DEXAMETHASONE; DIPHTHERIA TOXIN; LIGAND; MANNITOL; THIOESTER; TRANSFERRIN; TRANSFERRIN CRM107; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN EDEMA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CATHETER INFECTION; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; MAMMAL CELL; NEUROTOXICITY; NONHUMAN; POINT MUTATION; REVIEW; SEIZURE; SYSTEMIC DISEASE; THERMODYNAMICS; TOXICITY TESTING;

EID: 0344876636     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026246500788     Document Type: Review

References (35)

1. Fitzgerald DJ, Pastan I: Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 81: 1455-1463, 1989
2. Frankel A, Ring D, Bjorn M, et al.: Breast cancer immunotoxins. In: Ceriani RL (ed) Monoclonal Antibodies and Breast Cancer: Proceedings of the International Workshop on Monoclonal Antibodies and Breast Cancer. Martinus Nijhoff Publishing, Boston, 1985
3. Gilliland DG, Steplewski Z, Collier RJ, Mitchell KF, Chang TH, Koprowski H: Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 77: 4539-4543, 1980
4. Jansen FK, Blyhtman HE, Carriere D, et al.: Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62; 185-216, 1982
5. 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 61: 857-868, 1988
6. Puri RK, Leland P, Kreitman RJ, Pastan I: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL-4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58(4): 574-581, 1994
7. Trowbridge IS, Domingo DL: Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature 294: 171-173, 1981
8. Uhr JW: Immunotoxins: Harnessing nature's poisons. J Immunol 133: i-x, 1984
9. Youle RJ, Colombatti M: Immunotoxins: Monoclonal antibodies linked to toxin proteins for bone marrow transplantation and cancer therapy. In: Roth JA (ed) Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. Futura Publishing Co., New York, 173-213, 1986
10. Greenfield L, Johnson VG, Youle RJ: Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238; 536-539, 1987
11. Johnson VG, Wrobel C, Wilson D, et al.: Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 70: 240-248, 1989
12. Recht L, Torres CO, Smith TW, Raso V, Griffin TW: Transferrin receptor in normal and neoplastic brain tissue: Implications for brain tumor immunotherapy. J Neurosurg 72: 941-945, 1990
13. Faulk WP, His BL, Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. The Lancet 2: 390-392, 1980
14. Galbraith GMP, Galbraith RM, Faulk WP: Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunol 49: 215-222, 1980
15. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY: Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol 36: 539-545, 1983
16. Larrick JW, Cresswell P: Modulation of cell surface transferrin receptors by cellular density and state of activation. J Supramil Struct 11: 579-586, 1979
17. Shindelman JE, Ortmeyer AE, Sussman HH: Demonstration of the transferrin receptor in human breast tissue: Potential marker for identifying dividing cells. Int J Cancer 27: 329-334, 1981
18. Trowbridge IS, Newman RA, Domingo DL, Sauvage C: Transferrin receptors: Structure and function. Biochem Pharmacol 33: 925-932, 1984
19. Hamilton TA, Weiel JE, Adams DO: Expression of the transferrin receptor in murine peritoneal macrophages is modulated in the different stages of activation. J Immunol 132: 2285-2290, 1984
20. Klausner RD, VanRenswoude I, Ashwell G, et al.: Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem 258: 4715-4724, 1983
21. Angelova-Gateva P: Iron transferrin receptors in rat and human cerebrum. Agressologie 21: 27-30, 1980
22. Hill JM, Ruff MR, Weber RJ, Pert CB: Transferrin receptors in rat brain: Neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 82: 4553-4557, 1985
23. Connor JR, Fine RE: The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res 368: 319-328, 1986
24. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY: Transferrin receptor on endothelium of brain capillaries. Nature 312: 162-163, 1984
25. Johnson VG, Wilson D, Greenfield L, Youle RJ: The role of diphtheria toxin receptor in cytosol translocation. J Biol Chem 263: 1295-1300, 1988
26. Martell LA, Agrawal A, Ross DA, Muraszko KM: Efficacy of transferring receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53: 1348-1353, 1993
27. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH: Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 80: 520-526, 1994
28. Oldfield EH, Laske DW, Youle RJ: Physicians' IND Number BB4570, 1992
29. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076-2080, 1994
30. Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart-Henney PA, Koong S, Cummins A, Paik CH, and Oldfield EH: Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 87: 586-594, 1997
31. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med 3(12): 1362-1368, 1997
32. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of Chemotherapy Agents. Columbia University Press, New York, pp. 191-205, 1989
33. Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Morrison PF, Brechbiel MW, Oldfield EH: Successful and safe perfusion of the primate brainstem: In vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97: 905-913, Oct. 2002
34. Hagihara N, Walbridge S, Olson A, Oldfield E, Youle R: Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res 60: 230-234, 2000
35. Grant R, Slattery J, Gregor A, Whittle IR: Recording neurological impairment in clinical trials of glioma. J Neuro-Oncol 19: 37-49, 1994